
About Praxis Precision Medicines
Praxis Precision Medicines is a publicly listed company based in Cambridge (United States) founded in 2015. Therapies for brain disorders are developed by the company. Praxis Precision Medicines has raised $110 million across 1 funding round from investors including Blackstone, Citadel and Verition Fund Management. The company has 116 employees. Its chief executive, as recorded, is Marcio Souza. Its website praxismedicines.com draws about 36 thousand monthly visits. Praxis Precision Medicines offers products and services including Precision Therapies and Clinical Assets. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is Praxis Precision Medicines, Inc. Its competitors include Kriya Therapeutics, Sana Biotechnology and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Praxis Precision Medicines was founded in 2015 and is headquartered in Cambridge, United States. Therapies targeting brain disorders are developed within the biotechnology sector. Key candidates include Prax-114 for mood disorders, Prax-994 for movement disorders such as epilepsy, Prax-222 and Prx-120 for genetic epilepsies, and Prax-562 for pain disorders. Operations focus on advancing these treatments through research and development. Leadership is provided by CEO and President Marcio Souza.
- Headquarters Cambridge, United States
- Employees 116
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website praxismedicines.com
- Social LinkedIn Facebook Instagram
- Legal Name Praxis Precision Medicines, Inc.
- Net Profit-$303.27 M (USD)-65.88as on Dec 31, 2025
- EBITDA-$326.06 M (USD)-63.19as on Dec 31, 2025
- Total Equity Funding$110M (USD)
in 1 rounds
- Latest Funding Round$110M (USD), Series C
May 2020
- InvestorsBlackstone
& 11 more
- Employee Count116
Products & Services of Praxis Precision Medicines
Praxis Precision Medicines offers a comprehensive portfolio of products and services, including Precision Therapies and Clinical Assets.
Develops treatments for CNS disorders based on genetic insights.
Advances programs like EMBOLD for epilepsy treatment via genetics.
Funding Insights of Praxis Precision Medicines
Praxis Precision Medicines has successfully raised a total of $110M through 1 strategic funding round. The most recent funding activity was a Series C round of $110 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $110M
- Total Rounds 1
- Last Round Series C β $110M
- First Round $110M
(May 2020)
- Investors Count 12
All 1 funding rounds of Praxis Precision Medicines with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2020 | $110M | Series C | β | Eventide Funds |
12 investors in total: 12 institutional.
Investors in Praxis Precision Medicines
Praxis Precision Medicines has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Blackstone, Citadel and Verition Fund Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Biomedical innovations are transformed into therapies by Vida Ventures. | vidaventures.com | Boston, United States | ||
Early-stage startups are invested in by sector-agnostic VC fund. | irvinginvestors.com | New York, United States | ||
Venture capital fund focused on biotechnology startups | avorocapital.com | New York, United States | ||
Venture capital investments are provided by OCV Partners. | ocvpartners.com | Los Angeles, United States | ||
Eventide Mutual Funds is managed by Eventide Asset Management, offering investment solutions. | eventidefunds.com | Boston, United States | ||
Provider of investment & fund management services | 2008 | verition.com | Greenwich, United States | |
Manages alternative investments through equity, systematic, macro, and private strategies worldwide. | 2014 | point72.com | Stamford, United States | |
Long, short, event-driven, and multiple strategies are employed by Citadel. | 1990 | citadel.com | Chicago, United States |
Investor details for Praxis Precision Medicines
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Praxis Precision Medicines
58 people are tracked at Praxis Precision Medicines (34 in leadership, 6 in board & advisors, 18 in team); the tracked headcount is 116.
| Name | Role | Group |
|---|---|---|
Marcio Souza | CEO & President | Leadership |
Louie B. | Director Clinical Supply | Leadership |
Amber Roberts | Senior Director, Clinical Quality | Leadership |
Lyndsey Anderson | Associate Director | Leadership |
Tim Kelly | CFO | Leadership |
Alyssa Wyant | Chief Regulatory & Quality Officer | Leadership |
Megan Sniecinski | Chief Business Officer | Leadership |
Kelly McCue | Chief People Officer | Leadership |
Saba Jafarpour | Associate Medical Director- Clinical Development | Leadership |
Toni C. Meadows | Associate Director, Data Management | Leadership |
Hong Sun | Senior Vice President, Head Of Clinical Development | Leadership |
Steven Petrou | Co-Founder & Chief Scientific Officer | Leadership |
Kris Kahlig | VP Of Biology, Discovery Sciences | Leadership |
Karl Hansen | Chief Technical Operations Officer | Leadership |
Vincent Amoruccio | Vice President, Head Of Data Sciences | Leadership |
Laura McIntyre | Associate Director, Accounting | Leadership |
Doris Neville | Executive Director, CMC Head Of Engineering And Commercialization | Leadership |
Maribel Hernandez | Vp, Head Of Clinical Operations | Leadership |
Charmaine Manilay | Associate Director, Regulatory Writing And Operations | Leadership |
Ida Licata | Head Of Business Operations Outsourcing | Leadership |
38 more people are available in the full profile.
Complete people profiles for Praxis Precision Medicines
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Praxis Precision Medicines
Praxis Precision Medicines is a publicly listed company on the NASDAQ with ticker symbol PRAX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Oct 2020
- Listed onNASDAQ: PRAX
- Listed entityPraxis Precision Medicines, Inc.
- Exchange sectorHealth technology
- ISINUS74006W2070
- Share price$243.34 (-3.2% on the day) · 2026-10-13
- Market capitalisation$6.79B
- EPS (diluted, trailing year)$-12.94
- Volume (last session)622,168
Financials of Praxis Precision Medicines
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$303.3M | -$326.1M | |
| 2024 | $8.6M | -$182.8M | -$199.8M |
| 2023 | $2.5M | -$123.3M | -$125.9M |
| 2022 | -$214.0M | -$213.8M | |
| 2021 | -$167.1M | -$165.7M |
Detailed financial statements for Praxis Precision Medicines
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Praxis Precision Medicines
3 dated milestones of Praxis Precision Medicines across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Praxis Precision Medicines is founded.
- Funding First funding round of $110.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Praxis Precision Medicines
Praxis Precision Medicines has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Sana Biotechnology and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of Praxis Precision Medicines
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Praxis Precision Medicines
The website of Praxis Precision Medicines (praxismedicines.com) receives about 35.6K visits a month and ranks #1,244,570 among all websites worldwide, #1,572 in Biotechnology and Pharmaceuticals.
- Monthly visits35.6K
▲ 47.8% vs previous month
- Unique visitors12.4K
per month
- Global rank#1,244,570
among all websites
- Category rank#1,572
Health · Biotechnology and Pharmaceuticals
- Bounce rate50%
- Pages per visit1.6
- Average visit25 sec
- DevicesDesktop 32% Β· Mobile 68%
Websites whose visitors overlap most with Praxis Precision Medicines. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| servier.us | 100% | #2,050,491 | View details | ||
| paratekpharma.com | 99% | 4K | #5,533,702 | View details | |
| ensoma.com | 99% | 2.8K | #4,644,561 | View details | |
| pieris.com | 99% | View details | |||
| zealandpharma.com | 96% | 25.2K | #1,273,571 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 16 similar websites and full traffic analytics for Praxis Precision Medicines
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Praxis Precision Medicines (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Praxis Precision Medicines
Complete news archive for Praxis Precision Medicines
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Praxis Precision Medicines
Praxis Precision Medicines was founded in 2015 and raised its 1st funding round 5 years after it was founded.
Praxis Precision Medicines is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Marcio Souza is the CEO of Praxis Precision Medicines, as recorded in our data.
Praxis Precision Medicines is a funded company, having raised a total of $110M across 1 funding round to date. The company's 1st funding round was a Series C of $110M, raised on May 2020.
Praxis Precision Medicines has 116 employees.
Praxis Precision Medicines was founded in 2015 and is headquartered in Cambridge, United States. Therapies targeting brain disorders are developed within the biotechnology sector. Key candidates include Prax-114 for mood disorders, Prax-994 for movement disorders such as epilepsy, Prax-222 and Prx-120 for genetic epilepsies, and Prax-562 for pain disorders. Operations focus on advancing these treatments through research and development. Leadership is provided by CEO and President Marcio Souza.
Praxis Precision Medicines's top competitors include Sana Biotechnology, PureTech Health and Kriya Therapeutics.
Praxis Precision Medicines offers Precision Therapies and Clinical Assets.
Yes, Praxis Precision Medicines is publicly traded on NASDAQ under the ticker symbol PRAX.
Praxis Precision Medicines has 12 investors. Key investors include Blackstone, Citadel, Verition Fund Management, Novo Holdings, and Vida Ventures.
Praxis Precision Medicines operates through Praxis Precision Medicines, Inc..
